Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

115.30 +0.34 (+0.29%)
Streaming Delayed Price Updated: 2:55 PM EDT, Sep 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,163,649
Open 115.30
Bid (Size) 115.29 (1)
Ask (Size) 115.30 (7)
Prev. Close 114.96
Today's Range 115.11 - 116.02
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and... 
Via Benzinga
Exposures Product Safety
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained... 
Via Benzinga

Performance

YTD
+1.81%
+1.81%
1 Month
-0.84%
-0.84%
3 Month
-13.26%
-13.26%
6 Month
-8.15%
-8.15%
1 Year
+8.93%
+8.93%

More News

Read More
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck & Co Unusual Options Activity For September 23
Via Benzinga
Exploring NYSE:MRK's dividend characteristics.
Via Chartmill
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
From Merck & Co., Inc.
Via Business Wire
Pfizer Advances On Its Cancer Journey
Via Benzinga
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
From Merck & Co., Inc.
Via Business Wire
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
NYSE:MRK: good value for what you're paying.
Via Chartmill
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Via Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Via FinancialNewsMedia
Is It Too Late to Buy ServiceNow Stock?
Via The Motley Fool
A Closer Look at 8 Analyst Recommendations For Merck & Co
Via Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Via Benzinga
Exposures Product Safety
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
Via The Motley Fool
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
From Merck & Co., Inc.
Via Business Wire
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
Via Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Via Benzinga
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
Via MarketBeat
Exposures COVID-19 Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.